KIDNEY DISEASE

Potential new use of DXB’s drug in US$2.5 Billion market

Yesterday our 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), announced an agreement with the Australian Centre for Accelerating Diabetes Innovation to commence a clinical trial on Diabetic Kidney Disease expected Q4 2022.

DXB Actively Recruiting Patients Across the Globe, First Dosing Soon

DXB is a long-term position for us, and despite its share price performance over recent weeks, we’re quietly satisfied with its progress to date - especially on the FSGS front.

DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.

Earlier than Expected - DXB Gets First Regulatory Approval in Europe.

Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.

Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.